Priority Lists
Protocol Posting of
Activations
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer
| Study Coordinator(s) | Omer Kucuk, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons |
Closures
Amendments, Revisions, Memoranda
Phase III Randomized Trial of 12 Months VS 3 Months of Paclitaxel in Patients with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (Intergroup)
| Study Coordinator(s) | Maurie Markman, M.D., Bradley J. Monk, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Pathologists, Surgeons, GOG, NCORP |
Evaluation of the Combination of Docetaxel (Taxotere®)/ Carboplatin in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Phase II
| Study Coordinator(s) | Wolfram E. Samlowski, M.D., J. Philip Kuebler, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, NCORP |
A Phase II Study of Daunomycin and Ara-C Given by Continuous IV Infusion with PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older
| Study Coordinator(s) | Thomas R. Chauncey, M.D.,Ph.D., John E. Godwin, M.D., Alan F. List, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Jacqueline R. Batanian, Ph.D. |
| Participants | Pathologists, NCORP, Members |
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #6
A Phase II Study of Cisplatin Preceded by a 12-Hour Continuous Infusion of Concurrent Hydroxyurea and Cytosine Arabinoside (Ara-C) for Adult Patients with Malignant Gliomas
| Study Coordinator(s) | Lode J. Swinnen, M.D., Jeannette J. Townsend, M.D., Peter C. Burger, M.D. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP |
Revision #7
Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma, A BMT Study, Phase III
| Study Coordinator(s) | Alexander Fefer, M.D., John A. Thompson, M.D., Patricia K. Lillis-Hearne, M.D. |
| Participants | Limited Institutions: BMT Members |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required